THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

FDA panel backs Tysabri for Crohn's

Europeans refused to allow such use for Biogen MS drug

The Food and Drug Administration advisory panel meeting yesterday on Tysabri. The Food and Drug Administration advisory panel meeting yesterday on Tysabri. (Stephanie Kuykendal/Bloomberg News)
By Jeffrey Krasner
Globe Staff / August 1, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

A panel advising the Food and Drug Administration yesterday said the multiple sclerosis drug Tysabri, sold by Biogen Idec Inc. of Cambridge and Elan Corp. of Ireland, should be approved to treat Crohn's disease. (Full article: 631 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass